Myriad Genetics Inc (MYGN) Stock Price

MYGNStock

$3.98−50.74%52W

Market Cap$380.69M

P/E—

PEG Ratio1.24

Div yield—

Beta1.68

MYGN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-28.85%

Price vs S&P 500 (4W)0.58%

PEG Ratio1.24

VGM Score47.13

P/CF (Annual)211.49x

Book Value / Share (Quarterly)$3.18

P/TBV (Annual)2.67x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)6.72%

Cash Flow / Share (Quarterly)$-0.15

Price vs S&P 500 (YTD)-47.21%

Gross Margin (TTM)68.83%

Net Profit Margin (TTM)-13.96%

EPS (TTM)$-1.20

10-Day Avg Trading Volume1.69M

EPS Excl Extra (TTM)$-1.20

Revenue Growth (5Y)22.43%

EPS (Annual)$-3.95

ROI (Annual)-74.99%

Gross Margin (Annual)69.93%

Net Profit Margin (5Y Avg)-23.00%

Cash / Share (Quarterly)$1.21

Revenue Growth QoQ (YoY)-10.51%

ROA (Last FY)-51.78%

Revenue Growth TTM (YoY)-3.16%

EBITD / Share (TTM)$-0.52

ROE (5Y Avg)-33.33%

Operating Margin (TTM)-12.22%

Cash Flow / Share (Annual)$-0.27

P/B Ratio1.25x

P/B Ratio (Quarterly)1.77x

Net Income / Employee (Annual)$-135,500

EV / Revenue (TTM)0.48x

Net Interest Coverage (TTM)-44.41x

ROA (TTM)-16.39%

EV / EBITDA (TTM)43.88x

EPS Incl Extra (Annual)$-3.95

Current Ratio (Annual)2.49x

Quick Ratio (Quarterly)1.72x

3-Month Avg Trading Volume1.91M

52-Week Price Return-50.74%

Revenue / Employee (TTM)$298,700

Tangible BV / Share (Quarterly)$1.72

P/S Ratio (Annual)0.46x

Asset Turnover (Annual)1.17x

52-Week High$8.59

Operating Margin (5Y Avg)-24.72%

EPS Excl Extra (Annual)$-3.95

CapEx CAGR (5Y)21.85%

Tangible BV CAGR (5Y)-6.76%

26-Week Price Return-18.94%

Quick Ratio (Annual)1.99x

13-Week Price Return-35.60%

Total Debt / Equity (Annual)0.33x

Current Ratio (Quarterly)2.21x

Enterprise Value$386.19M

Revenue / Share Growth (5Y)17.37%

Asset Turnover (TTM)1.17x

Book Value / Share Growth (5Y)-19.56%

Revenue / Employee (Annual)$305,400

Inventory Turnover (Annual)8.53x

Pretax Margin (Annual)-47.92%

Cash / Share (Annual)$1.60

3-Month Return Std Dev112.62%

Gross Margin (5Y Avg)70.01%

Net Income / Employee (TTM)$-41,700

ROE (Last FY)-99.43%

Net Interest Coverage (Annual)-6.99x

EPS Basic Excl Extra (Annual)$-3.95

P/FCF (TTM)19.52x

Receivables Turnover (TTM)6.54x

Total Debt / Equity (Quarterly)0.40x

EPS Incl Extra (TTM)$-1.20

Receivables Turnover (Annual)6.97x

ROI (TTM)-24.18%

P/S Ratio (TTM)0.47x

Pretax Margin (5Y Avg)-25.29%

Revenue / Share (Annual)$8.90

Tangible BV / Share (Annual)$2.30

Forward P/E49.96x

Price vs S&P 500 (52W)-66.27%

Year-to-Date Return-35.28%

5-Day Price Return-5.24%

EPS Normalized (Annual)$-3.95

ROA (5Y Avg)-19.71%

Net Profit Margin (Annual)-44.38%

Month-to-Date Return-7.66%

Cash Flow / Share (TTM)$-2.62

EBITD / Share (Annual)$-3.60

Operating Margin (Annual)-46.96%

LT Debt / Equity (Annual)0.33x

P/CF (TTM)49.44x

ROI (5Y Avg)-27.93%

LT Debt / Equity (Quarterly)0.40x

EPS Basic Excl Extra (TTM)$-1.20

P/TBV (Quarterly)3.27x

P/B Ratio (Annual)1.56x

Inventory Turnover (TTM)8.48x

Pretax Margin (TTM)-13.86%

Book Value / Share (Annual)$3.94

Price vs S&P 500 (13W)-38.28%

Beta1.68x

P/FCF (Annual)1903.43x

Revenue / Share (TTM)$8.51

ROE (TTM)-32.59%

52-Week Low$2.74

vGradeC

gGradeC

mGradeD

vgmGradeC

MYGN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 30, 2026	-$0.06	-$0.25	-332.68%(-$0.19)
Q1 2026	May 5, 2026	-$0.07	-$0.09	-34.67%(-$0.02)
Q4 2025	Feb 23, 2026	-$0.02	$0.04	+348.29%(+$0.06)
Q3 2025	Nov 3, 2025	-$0.01	$0.00	+100.00%(+$0.01)
Q2 2025	Aug 5, 2025	-$0.01	$0.05	+724.22%(+$0.06)

MYGN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

2.63

2.60

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
MYGNMyriad Genetics Inc	C	C	D	0.5x	-3.2%	68.8%	—	$3.98
IDXXIdexx Laboratories Inc	D	B	B	9.7x	12.8%	62.5%	14.3%	$560.36
LNTHLantheus Holdings, Inc	C	B	B	4.2x	2.4%	61.0%	40.7%	$99.70
NEOGNeogen Corp	C	C	A	2.9x	-0.3%	47.4%	—	$11.81
CLDXCelldex Therapeutics, Inc	F	F	C	13683.0x	-97.3%	17.6%	—	$27.53
NTLAIntellia Therapeutics, Inc	D	D	C	26.9x	12.6%	—	—	$11.42
QDELQuidelOrtho Corporation Common Stock	C	C	C	0.3x	-2.5%	44.6%	—	$12.91
ACHVAchieve Life Sciences, Inc.	F	F	B	36.8x	-89.3%	—	—	$6.38
TKNOAlpha Teknova, Inc. Common Stock	D	C	B	8.7x	12.3%	34.6%	—	$7.08
NNNNAnbio Biotechnology Class A Ordinary Shares	F	C	F	34.0x	-5.7%	89.0%	—	$3.13
IMDXInsight Molecular Diagnostics Inc. Common Stock	F	D	C	59.0x	-60.8%	48.3%	—	$3.01
ICCCImmucell Corp	C	C	A	3.2x	8.5%	40.3%	—	$10.75
BMRABIOMERICA INC	B	D	B	1.9x	-16.2%	8.1%	—	$1.85
TRIBTrinity Biotech plc	B	D	C	0.1x	-16.6%	32.9%	—	$8.03
VNRXVolitionRx Limited	B	B	F	2.0x	86.3%	—	—	$0.18
CDIOCardio Diagnostics Holdings Inc. Common stock	—	D	C	345.9x	-25.9%	—	—	$1.69
QCLSQ/C Technologies, Inc. Common Stock	B	—	F	5.3x	—	24.7%	—	$0.54
VRAXVirax Biolabs Group Limited Ordinary Shares	—	B	F	156.9x	96.4%	62.0%	—	$1.45
CDIOWCardio Diagnostics Holdings Inc. Warrant	—	—	F	—	—	—	—	$0.01

About Myriad Genetics Inc

Myriad Genetics develops and commercializes molecular diagnostic tests that assess disease risk and guide treatment decisions across medical specialties. The company's portfolio includes BRACAnalysis CDx, GeneSight, MyChoice CDx, Prolaris, and other proprietary tests used to support earlier detection and precision treatment. Revenue is primarily generated in the United States with international operations.